Showing 338 results for "risdiplam"

SMA newborn screening seen as cost effective in real-world terms

The start of a newborn screening (NBS) program for spinal muscular atrophy (SMA), allowing early treatment for infants found to have the disease, added to healthy years of life for patients in Belgium, according to a real-world analysis of its cost-effectiveness. “Spinal muscular atrophy newborn screening coupled with early…

A look back at 2023, a year of contraction

On a Sunday morning in mid-November, I opened my email to a newsletter from one of my favorite writers, Catherine Andrews. In it, she named the past 15 years of her life as being particularly contractive. She struggled with everything, from her relationship with alcohol to dating and creativity.

Gene editing of SMN2 leads to normal SMN protein levels: Study

Researchers in the U.S. report using a gene-editing method to alter the SMN2 gene sequence, leading to normal levels of the survival motor neuron (SMN) — the protein that is lacking in spinal muscular atrophy — in early studies. These results were obtained in a cell line derived from…

Consistent DMT access is major concern for caregivers in Canada

Consistent access to disease-modifying therapies (DMTs) is a major concern for parent caregivers of children with spinal muscular atrophy (SMA) in Canada, a study reported. Barriers to such treatments, as described by caregivers, included variable regulatory approvals across different Canadian provinces, high costs, and insufficient healthcare infrastructure. “Our…

In life with SMA, I’m changing hustles like the seasons

One thing I’ve learned from not going through Singapore’s formal education system is this: When it’s time to be a working adult, to earn your keep, it’s incredibly hard to persuade someone to hire you if you have a blank résumé. Everyone has to start somewhere to gain employment,…

SMA varies with 4 SMN2 gene copies, gets worse with age

How spinal muscular atrophy (SMA) manifests among people who carry four copies of the SMN2 gene varies, ranging from type 2 to type 4, with functional abilities showing a tendency to decline with age, a study in Italy finds. Understanding how the disease progresses over time and what influences…